The #CoEpi group has been hard at work over the last week on #CoEpi: we have folks working on backend development, MVP (prototype) development, and both UX and front-end development for our full version of #CoEpi (see vision at CoEpi.org)
#CoEpi will be an app that prompts useful, relevant notifications (such as washing hands after changing locations), and helps you track & alert - if you want - your loved ones about symptoms of a contagious illness, or alert you if you might have been exposed by a close contact.
How can you help with #CoEpi? If you’re a mobile developer (Android, iOS, or #ReactNative), please reach out. We can also use help with backend development. But if that’s not your skillset, sign up to be an early tester here: forms.gle/KRaBNx8YfpvqZB…
Note that #CoEpi is an open source and #WeAreNotWaiting speed and style project. We are all volunteers spending nights/weekends/spare time working on #CoEpi. Given the spread of #COVID19, we can’t afford to wait.
Thanks to everyone who's helping fight the spread of #COVID19!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1/ What if there was a tool to help identify who might have exocrine pancreatic insufficiency (EPI/PEI)?
EPI is a significant issue for many people with diabetes (likely more common than gastroparesis or celiac).
Here's how such a tool can help PWD👇🏼🧵
#ADASciSessions #ADA2024
2/ The Exocrine Pancreatic Insufficiency Symptom Score (EPI/PEI-SS) has 15 symptoms, rated by how frequent they are and how bothersome they are (aka severity).
n=324 ppl participated in a real-world survey.
n=118 were people with diabetes (PWD)!
#ADASciSessions #ADA2024
3/ Methods:
EPI/PEI-SS scores were analyzed and compared between PWD (n=118), with EPI (T1D: n=14; T2D: n=20) or without EPI (T1D: n=78; T2D: n=6), and people without diabetes (n=206) with and without EPI.
📣 Presentation of the primary outcome results from the CREATE Trial, which assessed open source automated insulin delivery (AID) compared to sensor-augmented pump therapy (SAPT) in adults & kids with T1D, at #ADA2022!
The CREATE trial aimed to study the efficacy and safety of an open source automated insulin delivery system, with a large scale, long term randomized controlled trial.
I just realized it's been 3 (!) years since I published my book on automated insulin delivery, with the goal of helping increased conversation and understanding of AID technology for people with diabetes, their loved ones, and healthcare providers!
I'm still very proud that it is available to read for free online, free to download a PDF (both of which have been done thousands of times each: ArtificialPancreasBook.com), or as an e-book, paperback, and now hardback copy. Proceeds from the purchased copies go to Life For A Child.
And, more recently, it has also been translated into French by the wonderful Dr. Mihaela Muresan and Olivier Legendre!
The French translation is available in Kindle, paperback, hardback, or free PDF download formats as well.
1/THREAD - my presentation is kicking off at #EASD2020 about open source automated insulin delivery.
(You can see a full version of my presentation here: bit.ly/DanaMLewisEASD…, or read the summary below!)
Note we should differentiate between open source (where the source of something is open), and DIY (do-it-yourself) implementations of open source code. Open source means it can be reviewed and used by individuals (thus, DIY or #DIYAPS) or by companies.
Poster 988-P at #ADA2020 by Jennifer Zabinsky, Haley Howell, Alireza Ghezavati, @DanaMLewis Andrew Nguyen, and Jenise Wong: “Do-It-Yourself Artificial Pancreas Systems Reduce Hyperglycemia Without Increasing Hypoglycemia”
This was a retrospective double cohort study that evaluated data from the @OpenAPS Data Commons (data ranged from 2017-2019) and compared it to conventional sensor-augmented pump (SAP) therapy from the @Tidepool_org Big Data Donation Project. #ADA2020
One month of CGM data (with more than 70% of the month spent using CGM), as long as they were >1 year of living with T1D, was used from the @OpenAPS Data Commons. People could be using any type of DIYAPS (OpenAPS, Loop, or AndroidAPS) and there were no age restrictions. #ADA2020
Poster 99-LB at #ADA2020 by @danamlewis, @azure_dominique, and Lance Kriegsfeld, “Multi-Timescale Interactions of Glucose and Insulin in Type 1 Diabetes Reveal Benefits of Hybrid Closed Loop Systems“
Background - Blood glucose and insulin exhibit coupled biological rhythms at multiple timescales, including hours (ultradian, UR) and the day (circadian, CR) in individuals without diabetes. But, biological rhythms in longitudinal data have not been mapped in T1D. #ADA2020
It is not known exactly how glucose and insulin rhythms compare between T1D and non-T1D, and whether rhythms are affected by type of therapy (Sensor Augmented Pump (SAP) or Hybrid Closed Loop (HCL)). #ADA2020